{
  "id": "5c6f6d997c78d69471000055",
  "type": "yesno",
  "question": "Is pimavanserin effective for Parkinson's disease psychosis?",
  "ideal_answer": "Yes. Pimavanserin is effective for treating Parkinson's disease psychosis. It is a highly selective serotonin 5-HT2A receptor inverse agonist/antagonist.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/28493654",
    "http://www.ncbi.nlm.nih.gov/pubmed/24183563",
    "http://www.ncbi.nlm.nih.gov/pubmed/27609312",
    "http://www.ncbi.nlm.nih.gov/pubmed/29497575",
    "http://www.ncbi.nlm.nih.gov/pubmed/29185542",
    "http://www.ncbi.nlm.nih.gov/pubmed/29047301",
    "http://www.ncbi.nlm.nih.gov/pubmed/26908168",
    "http://www.ncbi.nlm.nih.gov/pubmed/28385039",
    "http://www.ncbi.nlm.nih.gov/pubmed/28622212",
    "http://www.ncbi.nlm.nih.gov/pubmed/28375643",
    "http://www.ncbi.nlm.nih.gov/pubmed/29452684",
    "http://www.ncbi.nlm.nih.gov/pubmed/28880354",
    "http://www.ncbi.nlm.nih.gov/pubmed/29098976",
    "http://www.ncbi.nlm.nih.gov/pubmed/29185820",
    "http://www.ncbi.nlm.nih.gov/pubmed/29105858",
    "http://www.ncbi.nlm.nih.gov/pubmed/27262680",
    "http://www.ncbi.nlm.nih.gov/pubmed/30298184",
    "http://www.ncbi.nlm.nih.gov/pubmed/26744739",
    "http://www.ncbi.nlm.nih.gov/pubmed/19907417",
    "http://www.ncbi.nlm.nih.gov/pubmed/28817967",
    "http://www.ncbi.nlm.nih.gov/pubmed/27830568",
    "http://www.ncbi.nlm.nih.gov/pubmed/29955528"
  ],
  "snippets": [
    {
      "text": "Two cases of Parkinson's disease with an unusual delusional misidentification, intermetamorphosis, are presented, along with their improvement with pimavanserin, a novel atypical antipsychotic medication.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29185820",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "RATIONALE: Pimavanserin, a selective serotonin 2A receptor inverse agonist, is a promising candidate for treating Parkinson's disease psychosis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29105858",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "OBJECTIVE: Our aim was to describe the efficacy and tolerability of pimavanserin, a highly selective serotonin 5-HT2A receptor inverse agonist/antagonist indicated for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP), using the metrics of number needed to treat (NNT) and number needed to harm (NNH).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29098976",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Pimavanserin: novel pharmacotherapy for Parkinson's disease psychosis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29047301",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "INTRODUCTION: Pimavanserin is the first FDA-approved atypical antipsychotic drug indicated for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP)",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29047301",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "A pivotal phase III clinical trial demonstrated significant improvement in PDP symptoms in patients receiving pimavanserin compared to placebo-treated patients. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29047301",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Pimavanserin's mechanism of action might contribute to its unique psychopharmacological properties in the improved treatment of PDP, and perhaps psychosis in other diseases including schizophrenia and dementia-related psychosis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29047301",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Pimavanserin (Nuplazid\u2122) for the treatment of Parkinson disease psychosis: A review of the literature.Options for the treatment of Parkinson disease psychosis are limited. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29955528",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Pimavanserin for the treatment of Parkinson's disease psychosis.Pimavanserin is an antipsychotic with a unique mechanism of action (5-HT2A receptor inverse agonist) and no measurable dopaminergic activity; it has been demonstrated to be efficacious, well tolerated and safe for the treatment of PDP. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27609312",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "A Retrospective Study of Pimavanserin Use in a Movement Disorders Clinic.Pimavanserin, a 5-HT2A inverse agonist, was commercially released in the United States in April 2016 for the treatment of Parkinson disease psychosis. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28622212",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "receptor inverse agonist pimavanserin was recently approved by the US FDA for the treatment of PDP and may prove to be a more targeted therapy without the downsides of atypical antipsychotics.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27830568",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Evidence-Based Review of Pharmacotherapy Used for Parkinson's Disease Psychosis.Despite lack of rigor in study designs, published data to date suggest that clozapine and pimavanserin should be considered drugs of choice to treat PD psychosis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28385039",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Pimavanserin: A novel therapeutic option for Parkinson disease psychosis.While pimavanserin appears to be a safe, effective, and well-tolerated therapeutic option for PDP, additional clinical trials and open-label extension studies are needed to determine the long-term safety and efficacy of this promising therapy. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29185542",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Objective: Pimavanserin is the first United States Food and Drug Administration (FDA)-approved treatment for Parkinson's disease psychosis (PDP).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29497575",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Pimavanserin: A Novel Drug Approved to Treat Parkinson's Disease Psychosis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29497575",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "CONCLUSIONS\nPimavanserin is the only FDA-approved treatment for the hallucinations and delusions seen in patients with psychosis of Parkinson's disease.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28493654",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "OBJECTIVE\nTo summarize the US Food and Drug Administration's (FDA's) review of the safety and effectiveness for pimavanserin, an atypical antipsychotic, for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28493654",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "RESULTS\nPimavanserin 34 mg/d was effective in treating hallucinations and delusions associated with Parkinson's disease.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28493654",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND\nPimavanserin is a selective 5-HT2A receptor inverse agonist and antagonist approved in the USA for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29452684",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Pimavanserin is the first FDA-approved atypical antipsychotic drug indicated for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29047301",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "INTERPRETATION\nPimavanserin may benefit patients with Parkinson's disease psychosis for whom few other treatment options exist.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24183563",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Pimavanserin (ACP-103) is a selective inverse agonist of the 5-hydroxytryptamine 2A (5-HT2A) receptor intended to treat patients with Parkinson's disease psychosis (PDP).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26744739",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "INTERPRETATION\nPimavanserin showed efficacy in patients with Alzheimer's disease psychosis at the primary endpoint (week 6) with an acceptable tolerability profile and without negative effect on cognition.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29452684",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "[Pimavanserin: a new treatment for the Parkinson's disease psychosis].",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28880354",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Pimavanserin, a serotonin(2A) receptor inverse agonist, for the treatment of parkinson's disease psychosis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/19907417",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Pimavanserin, a selective 5-HT2A inverse agonist/antagonist, was approved in the U.S. for treating hallucinations and delusions associated with Parkinson's disease psychosis (PDP).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30298184",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Pimavanserin: A Novel Antipsychotic for Parkinson's Disease Psychosis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28375643",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "CONCLUSIONS Pimavanserin is the only FDA-approved treatment for the hallucinations and delusions seen in patients with psychosis of Parkinson's disease.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28493654",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "OBJECTIVE To summarize the US Food and Drug Administration's (FDA's) review of the safety and effectiveness for pimavanserin, an atypical antipsychotic, for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28493654",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "RESULTS Pimavanserin 34 mg/d was effective in treating hallucinations and delusions associated with Parkinson's disease.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28493654",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "If this is granted, we believe the evidence of Pimavanserin efficacy, safety and tolerability will position this medication as the first choice for treatment of Parkinson's disease psychosis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26908168",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The development of pimavanserin as an antipsychotic opened a new therapeutic avenue in the treatment of PDP as well as targeting psychosis in other disorders such as Alzheimer's disease.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28817967",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "OBJECTIVE To review the pharmacology, pharmacokinetics, efficacy, safety, and place in therapy of pimavanserin for the treatment of hallucinations and delusions of Parkinson's disease psychosis (PDP).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28375643",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "INTERPRETATION Pimavanserin may benefit patients with Parkinson's disease psychosis for whom few other treatment options exist.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24183563",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "<b>OBJECTIVE</b>: To summarize the US Food and Drug Administration's (FDA's) review of the safety and effectiveness for pimavanserin, an atypical antipsychotic, for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28493654",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Data were available from 616 patients with Parkinson's disease with hallucinations and delusions who received at least 1 dose of pimavanserin, with a total exposure of 825 patient-years in the Parkinson's disease psychosis population.<br><b>RESULTS</b>: Pimavanserin 34 mg/d was effective in treating hallucinations and delusions associated with Parkinson's disease.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28493654",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Pimavanserin did not worsen motor function, an adverse effect commonly observed with other antipsychotics, probably because of a lack of consequential dopamine binding.<br><b>CONCLUSIONS</b>: Pimavanserin is the only FDA-approved treatment for the hallucinations and delusions seen in patients with psychosis of Parkinson's disease.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28493654",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Pimavanserin (Nuplazid\u2122) is a selective and potent serotonin 2A (5-HT2A) receptor inverse agonist and antagonist developed by ACADIA Pharmaceuticals that has been approved in the US as a treatment for patients with hallucinations and delusions associated with Parkinson's disease psychosis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27262680",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "This article summarizes the milestones in the development of pimavanserin leading to this first approval for the treatment of hallucinations and delusions in patients with Parkinson's disease psychosis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27262680",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In a Phase 2 study with pimavanserin in Alzheimer's disease psychosis, pimavanserin significantly (p=0.045) improved psychosis at Week 6 vs. placebo on the NPI-NH Psychosis Score (PS).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30298184",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "To summarize the US Food and Drug Administration's (FDA's) review of the safety and effectiveness for pimavanserin, an atypical antipsychotic, for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28493654",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Pimavanserin is the only FDA-approved treatment for the hallucinations and delusions seen in patients with psychosis of Parkinson's disease.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28493654",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Pimavanserin 34 mg/d was effective in treating hallucinations and delusions associated with Parkinson's disease.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28493654",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "Yes"
}